

Supplemental Reference List

S126. von Bernuth, H., Picard, C., Jin, Z., Pankla, R., Xiao, H., Ku, C.L., Chrabieh, M., Mustapha, I.B., Ghandil, P., Camcioglu, Y., et al. 2008. Pyogenic bacterial infections in humans with MyD88 deficiency. *Science*. **321**:691–696.

S127. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. 2000. A Toll-like receptor recognizes bacterial DNA. *Nature*. **408**:740–745.

S128. Plitas, G., Burt, B.M., Nguyen, H.M., Bamboat, Z.M., and DeMatteo, R.P. 2008. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. *J. Exp. Med.* **205**:1277–1283.

S129. Scumpia, P.O., McAuliffe, P.F., O'Malley, K.A., Ungaro, R., Uchida, T., Matsumoto, T., Remick, D.G., Clare-Salzler, M.J., Moldawer, L.L., and Efron, P.A. 2005. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. *J. Immunol.* **175**:3282–3286.

S130. Hacker, H., Mischak, H., Miethke, T., Liptay, S., Schmid, R., Sparwasser, T., Heeg, K., Lipford, G.B., and Wagner, H. 1998. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. *Embo J* **17**:6230–6240.

S131. Ertel, W., Morrison, M.H., Ayala, A., and Chaudry, I.H. 1992. Chloroquine attenuates hemorrhagic shock-induced immunosuppression and decreases susceptibility to sepsis. *Arch Surg* **127**:70-75; discussion 75–76.

S132. Bhan, U., Lukacs, N.W., Osterholzer, J.J., Newstead, M.W., Zeng, X., Moore, T.A., McMillan, T.R., Krieg, A.M., Akira, S., and Standiford, T.J. 2007. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. *J. Immunol.* **179**:3937–3946.

S133. Sjolinder, H., Mogensen, T.H., Kilian, M., Jonsson, A.B., and Paludan, S.R. 2008. Important role for Toll-like receptor 9 in host defense against meningococcal sepsis. *Infect Immun* **76**:5421–5428.

S134. Kang, D.H., and Johnson, R.J. 2003. Vascular endothelial growth factor: a new

player in the pathogenesis of renal fibrosis. *Curr Opin Nephrol Hypertens* **12**:43–49.

S135. Weis, S.M., and Cheresch, D.A. 2005. Pathophysiological consequences of VEGF-induced vascular permeability. *Nature*. **437**:497–504.

S136. Pickkers, P., Sprong, T., Eijk, L., Hoeven, H., Smits, P., and Deuren, M. 2005. Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. *Shock* **24**:508–512.

S137. van der Flier, M., van Leeuwen, H.J., van Kessel, K.P., Kimpen, J.L., Hoepelman, A.I., and Geelen, S.P. 2005. Plasma vascular endothelial growth factor in severe sepsis. *Shock* **23**:35–38.

S138. Yano, K., Liaw, P.C., Mullington, J.M., Shih, S.C., Okada, H., Bodyak, N., Kang, P.M., Toltl, L., Belikoff, B., Buras, J., et al. 2006. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. *J. Exp. Med.* **203**:1447–1458.

S139. Tsao, P.N., Chan, F.T., Wei, S.C., Hsieh, W.S., Chou, H.C., Su, Y.N., Chen, C.Y., Hsu, W.M., Hsieh, F.J., and Hsu, S.M. 2007. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. *Crit Care Med* **35**:1955–1960.

S140. Ward, P.A. 2004. The dark side of C5a in sepsis. *Nat Rev Immunol* **4**:133–142.

S141. Rittirsch, D., Flierl, M.A., Nadeau, B.A., Day, D.E., Huber-Lang, M., Mackay, C.R., Zetoune, F.S., Gerard, N.P., Cianflone, K., Kohl, J., et al. 2008. Functional roles for C5a receptors in sepsis. *Nat. Med.* **14**:551–557.

S142. Huber-Lang, M., Sarma, V.J., Lu, K.T., McGuire, S.R., Padgaonkar, V.A., Guo, R.F., Younkin, E.M., Kunkel, R.G., Ding, J., Erickson, R., et al. 2001. Role of C5a in multiorgan failure during sepsis. *J. Immunol.* **166**:1193–1199.

S143. Marik, P.E., Pastores, S.M., Annane, D., Meduri, G.U., Sprung, C.L., Arlt, W., Keh, D., Briegel, J., Beishuizen, A., Dimopoulou, I., et al. 2008. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. *Crit Care Med* **36**:1937–1949.

S144. Minneci, P.C., Deans, K.J., Banks, S.M., Eichacker, P.Q., and Natanson, C. 2004. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. *Ann Intern Med* **141**:47–56.

S145. Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., Wang, H., Abumrad, N., Eaton, J.W., and Tracey, K.J. 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature*. **405**:458–462.

S146. Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S., Li, J.H., Wang, H., Yang, H., Ulloa, L., et al. 2003. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. *Nature*. **421**:384–388.

S147. Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E.J., et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. *Nat. Med.* **10**:1216–1221.

S148. Huston, J.M., Ochani, M., Rosas-Ballina, M., Liao, H., Ochani, K., Pavlov, V.A., Gallowitsch-Puerta, M., Ashok, M., Czura, C.J., Foxwell, B., et al. 2006. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. *J. Exp. Med.* **203**:1623–1628.

S149. Miksa, M., Wu, R., Zhou, M., and Wang, P. 2005. Sympathetic excitotoxicity in sepsis: pro-inflammatory priming of macrophages by norepinephrine. *Front Biosci* **10**:2217–2229.

S150. Gonzalez-Rey, E., Chorny, A., and Delgado, M. 2007. Regulation of immune tolerance by anti-inflammatory neuropeptides. *Nat Rev Immunol* **7**:52–63.

S151. Star, R.A., Rajora, N., Huang, J., Stock, R.C., Catania, A., and Lipton, J.M. 1995. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. *Proc. Natl. Acad. Sci. U. S. A.* **92**:8016–8020.

S152. Kohda, Y., Chiao, H., and Star, R.A. 1998. alpha-Melanocyte-stimulating hormone and acute renal failure. *Curr Opin Nephrol Hypertens* **7**:413–417.

S153. Flierl, M.A., Stahel, P.F., Rittirsch, D., Huber-Lang, M., Niederbichler, A.D., Hoesel, L.M., Touban, B.M., Morgan, S.J., Smith, W.R., Ward, P.A., et al. 2009. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. *Crit Care* **13**:R12.

S154. Catania, A., Cutuli, M., Garofalo, L., Airaghi, L., Valenza, F., Lipton, J.M., and Gattinoni, L. 2000. Plasma concentrations and anti-L-cytokine effects of alpha-melanocyte stimulating hormone in septic patients. *Crit Care Med* **28**:1403–1407.

S155. Lipton, J.M., Ceriani, G., Macaluso, A., McCoy, D., Carnes, K., Biltz, J., and Catania, A. 1994. Antiinflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic inflammation. *Ann N Y Acad Sci* **741**:137–148.

S156. Dixit, V.D., Schaffer, E.M., Pyle, R.S., Collins, G.D., Sakthivel, S.K., Palaniappan, R., Lillard, J.W., Jr., and Taub, D.D. 2004. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. *J. Clin. Invest.* **114**:57–66.

S157. Li, W.G., Gavrilu, D., Liu, X., Wang, L., Gunnlaugsson, S., Stoll, L.L., McCormick, M.L., Sigmund, C.D., Tang, C., and Weintraub, N.L. 2004. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. *Circulation* **109**:2221–2226.

S158. Chorny, A., Anderson, P., Gonzalez-Rey, E., and Delgado, M. 2008. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. *J. Immunol.* **180**:8369–8377.

S159. Wu, R., Dong, W., Cui, X., Zhou, M., Simms, H.H., Ravikumar, T.S., and Wang, P. 2007. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. *Ann Surg* **245**:480–486.

S160. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S., Weinrauch, Y., and Zychlinsky, A. 2004. Neutrophil extracellular traps kill bacteria. *Science.* **303**:1532–1535.

S161. Clark, S.R., Ma, A.C., Tavener, S.A., McDonald, B., Goodarzi, Z., Kelly, M.M., Patel, K.D., Chakrabarti, S., McAvoy, E., Sinclair, G.D., et al. 2007. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. *Nat. Med.* **13**:463–469.

S162. Andonegui, G., Kerfoot, S.M., McNagny, K., Ebbert, K.V., Patel, K.D., and Kubes, P. 2005. Platelets express functional Toll-like receptor-4. *Blood.* **106**:2417–2423.

S163. Asaduzzaman, M., Lavasani, S., Rahman, M., Zhang, S., Braun, O., Jeppsson, B., and Thorlacius, H. 2009. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. *Crit Care Med In press.*

S164. Le Blanc, K., and Ringden, O. 2007. Immunomodulation by mesenchymal stem cells and clinical experience. *J Intern Med* **262**:509–525.

S165. Rasmusson, I. 2006. Immune modulation by mesenchymal stem cells. *Exp Cell Res* **312**:2169–2179.

S166. Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G.L., Pistoia, V., et al. 2006. Human mesenchymal stem cells modulate B-cell functions. *Blood*. **107**:367–372.

S167. Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., Uzunel, M., and Ringden, O. 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* **363**:1439–1441.

S168. Gupta, N., Su, X., Popov, B., Lee, J.W., Serikov, V., and Matthay, M.A. 2007. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. *J. Immunol.* **179**:1855–1863.

S169. Bi, B., Schmitt, R., Israilova, M., Nishio, H., and Cantley, L.G. 2007. Stromal cells protect against acute tubular injury via an endocrine effect. *J Am Soc Nephrol* **18**:2486–2496.

S170. Togel, F., Hu, Z., Weiss, K., Isaac, J., Lange, C., and Westenfelder, C. 2005. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. *Am. J. Physiol. Renal Physiol* **289**:F31–42.

S171. Nemeth, K., Leelahavanichkul, A., Yuen, P.S., Mayer, B., Parmelee, A., Doi, K., Robey, P.G., Leelahavanichkul, K., Koller, B.H., Brown, J.M., et al. 2009. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat. Med.* **15**:42–49.

S172. Gonzalez-Rey, E., Gonzalez, M.A., Rico, L., Buscher, D., and Delgado, M. 2009. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. *Gut*.

S173. Knaus, W.A., Draper, E.A., Wagner, D.P., and Zimmerman, J.E. 1985. APACHE II: a severity of disease classification system. *Crit Care Med* **13**:818–829.

S174. Vincent, J.L., Moreno, R., Takala, J., Willatts, S., De Mendonca, A., Bruining, H., Reinhart, C.K., Suter, P.M., and Thijs, L.G. 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* **22**:707–710.

S175. Doi, K., Yuen, P.S., Eisner, C., Hu, X., Leelahavanichkul, A., Schnermann, J., and Star, R.A. in press. Reduced creatinine production limits serum creatinine as an indicator of acute kidney injury in sepsis. *J Am Soc Nephrol*.

S176. Coca, S.G., Yalavarthy, R., Concato, J., and Parikh, C.R. 2008. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. *Kidney Int* **73**:1008–1016.

S177. Trof, R.J., Di Maggio, F., Leemreis, J., and Groeneveld, A.B. 2006. Biomarkers of acute renal injury and renal failure. *Shock* **26**:245–253.

S178. Bagshaw, S.M., Langenberg, C., Haase, M., Wan, L., May, C.N., and Bellomo, R. 2007. Urinary biomarkers in septic acute kidney injury. *Intensive Care Med* **33**:1285–1296.

S179. Natanson, C., Eichenholz, P.W., Danner, R.L., Eichacker, P.Q., Hoffman, W.D., Kuo, G.C., Banks, S.M., MacVittie, T.J., and Parrillo, J.E. 1989. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. *J. Exp. Med.* **169**:823–832.

S180. Ludwig, J.A., and Weinstein, J.N. 2005. Biomarkers in cancer staging, prognosis and treatment selection. *Nat Rev Cancer* **5**:845–856.

S181. Eichacker, P.Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S.M., Gerstenberger, E.P., Fitz, Y., Danner, R.L., and Natanson, C. 2002. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. *Am J Respir Crit Care Med* **166**:1197–1205.

S182. Carlet, J., Cohen, J., Calandra, T., Opal, S.M., and Masur, H. 2008. Sepsis: time to reconsider the concept. *Crit Care Med* **36**:964–966.

S183. Shorr, A.F., Nelson, D.R., Wyncoll, D.L., Reinhart, K., Brunkhorst, F., Vail, G.M., and Janes, J. 2008. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). *Crit Care* **12**:R45.

S184. Carter, S., and Slavik, M. 1974. Chemotherapy of cancer. *Annual Review of Pharmacology* **14**:157–183.

S185. Richman, D.D. 2001. HIV chemotherapy. *Nature*. **410**:995–1001.

S186. Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., and Tomlanovich, M. 2001. Early goal-directed therapy in the treatment of severe

sepsis and septic shock. *N. Engl. J. Med.* **345**:1368–1377.

S187. Polpitiya, A.D., McDunn, J.E., Burykin, A., Ghosh, B.K., and Cobb, J.P. 2009. Using systems biology to simplify complex disease: immune cartography. *Crit Care Med* **37**:S16–21.

S188. Tobert, J.A. 2003. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. *Nat Rev Drug Discov* **2**:517–526.

S189. Lotze, M.T., and Tracey, K.J. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol* **5**:331–342.

S190. Hotchkiss, R.S., and Nicholson, D.W. 2006. Apoptosis and caspases regulate death and inflammation in sepsis. *Nat Rev Immunol* **6**:813–822.

S191. Guo, R.F., Huber-Lang, M., Wang, X., Sarma, V., Padgaonkar, V.A., Craig, R.A., Riedemann, N.C., McClintock, S.D., Hlaing, T., Shi, M.M., et al. 2000. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. *J. Clin. Invest.* **106**:1271–1280.

S192. Zappitelli, M., Washburn, K.K., Arikan, A.A., Loftis, L., Ma, Q., Devarajan, P., Parikh, C.R., and Goldstein, S.L. 2007. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. *Crit Care* **11**:R84.

S193. Wheeler, D.S., Devarajan, P., Ma, Q., Harmon, K., Monaco, M., Cvijanovich, N., and Wong, H.R. 2008. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. *Crit Care Med* **36**:1297–1303.

S194. Liangos, O., Perianayagam, M.C., Vaidya, V.S., Han, W.K., Wald, R., Tighiouart, H., MacKinnon, R.W., Li, L., Balakrishnan, V.S., Pereira, B.J., et al. 2007. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. *J Am Soc Nephrol* **18**:904–912.

S195. Nakamura, T., Sugaya, T., and Koide, H. 2009. Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. *Shock* **31**:454–459.

S196. Washburn, K.K., Zappitelli, M., Arikan, A.A., Loftis, L., Yalavarthy, R., Parikh, C.R., Edelstein, C.L., and Goldstein, S.L. 2008. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. *Nephrol Dial Transplant* **23**:566–572.

S197. Zhou, H., Cheruvanky, A., Hu, X., Matsumoto, T., Hiramatsu, N., Cho, M.E., Berger, A., Leelahavanichkul, A., Doi, K., Chawla, L.S., et al. 2008. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. *Kidney Int* **74**:613–621.

S198. Dear, J.W., Leelahavanichkul, A., Aponte, A., Hu, X., Constant, S.L., Hewitt, S.M., Yuen, P.S., and Star, R.A. 2007. Liver proteomics for therapeutic drug discovery: inhibition of the cyclophilin receptor CD147 attenuates sepsis-induced acute renal failure. *Crit Care Med* **35**:2319–2328.